![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/01/2891804/0/en/Cullinan-Therapeutics-Announces-Positive-Initial-Data-from-Pivotal-Phase-2b-REZILIENT1-Study-of-Zipalertinib.html
https://www.globenewswire.com/news-release/2024/05/24/2887953/0/en/Cullinan-Therapeutics-to-Participate-in-Fireside-Chat-at-TD-Cowen-5th-Annual-Oncology-Innovation-Summit.html
https://www.globenewswire.com/news-release/2024/05/23/2887705/0/en/Cullinan-Therapeutics-to-Present-First-Data-for-CLN-619-a-Novel-Anti-MICA-B-Antibody-in-Combination-with-a-Checkpoint-Inhibitor-and-Updated-Monotherapy-Data-at-ASCO-2024.html
https://www.globenewswire.com/news-release/2024/05/15/2882878/0/en/Cullinan-Therapeutics-Provides-Corporate-Update-and-Reports-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/04/29/2871076/0/en/Cullinan-Therapeutics-Announces-Appointment-of-Mary-Kay-Fenton-as-Chief-Financial-Officer.html
https://finance.yahoo.com/news/why-cullinan-therapeutics-stock-trading-202917676.html
https://www.globenewswire.com/news-release/2024/04/24/2868766/0/en/Cullinan-Therapeutics-to-Present-Clinical-Data-from-Phase-1-Study-Evaluating-Novel-Anti-MICA-B-Antibody-CLN-619-as-Monotherapy-and-in-Combination-with-a-Checkpoint-Inhibitor-in-Pat.html
https://www.biopharmadive.com/news/cullinan-oncology-autoimmune-lupus-strategy-shift/713296/
https://www.globenewswire.com/news-release/2024/04/16/2863448/0/en/Cullinan-Therapeutics-Announces-Strategic-Expansion-into-Autoimmune-Diseases.html
https://www.globenewswire.com/news-release/2024/04/16/2863418/0/en/Cullinan-Therapeutics-Announces-Oversubscribed-280-million-Private-Placement.html